Post-Catheter Ablation Long-Term Antithrombotic Strategies in Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials

Figures

• 

  Figure 1.. Network meta-analysis forest plots: forest plots from the network meta-analysis using no antithrombotic therapy as the reference comparator. Incidence rates are reported per 100 patient-years. A, Ischemic stroke. B, Transient ischemic attack (TIA). C, Major bleeding. D, Clinically relevant nonmajor bleeding. IRR indicates incidence rate ratio; LAAO, left atrial appendage occlusion; and OAC, oral anticoagulation.

• 

  Figure 2.. Direct comparison of long-term anticoagulation and anticoagulation discontinuation: forest plots from the meta-analysis comparing no antithrombotic therapy and oral anticoagulation. A, Ischemic stroke. B, Transient ischemic attack (TIA). C, Major bleeding. D, Clinically relevant nonmajor bleeding. ALONE-AF indicates Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation; CRNMB, Clinically Relevant Nonmajor Bleeding; IRR, Incidence Rate Ratio; OAC, Oral Anticoagulation; ODIn-AF, Prevention of Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation; and OCEAN, Optimal Anticoagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation.

• 

  Figure 3.. Pooled incidence rates of events. Pooled incidence rate meta-analysis reported as events per 100 person-years for (A) patients receiving oral anticoagulation and (B) patients without antithrombotic therapy. ALONE-AF indicates Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation; IR, Incidence Rate; OCEAN, Optimal Anticoagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation; ODIn-AF, Prevention of Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation; and OPTION, Comparison of Anticoagulation with Left Atrial Appendage Closure After Atrial Fibrillation Ablation.

• 

  Figure 4.. Subgroup analysis of high-thromboembolic-risk patients: pooled incidence rate meta-analysis (events per 100 person-years) for stroke in patients without antithrombotic therapy and with a CHA2DS2-VASc score ≥3. ALONE-AF indicates Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation; IR, Incidence Rate; OCEAN, Optimal Anticoagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation; and ODIn-AF, Prevention of Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation.